Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Motivational Enhancement to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1
This study has been completed.
Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00032981
  Purpose

The purpose of this study is to evaluate the therapeutic usefulness of incorporating Motivational Enhancement Treatment into the standard drug abuse treatment entry process of Community Treatment Programs on improving treatment engagement, retention, and outcome.


Condition Intervention Phase
Substance-Related Disorders
Behavioral: Behavior Therapy
Phase III

U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized
Official Title: Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Retention
  • HIV risk behaviors
  • Psychosocial functioning

Estimated Enrollment: 561
Study Start Date: May 2001
Study Completion Date: August 2004
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)
Detailed Description:

Participants seeking treatment at the participating CTPs will be randomly assigned to either "standard" or "MET/MI" treatment, with a 1- and 3-month follow-up. Primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). Secondary outcomes will include motivation, psychosocial functioning, HIV risk behaviors, treatment utilization, and patient satisfaction. Process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively MET/MI was implemented. Participating CTPs will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. Thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either: 1) Random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of MET. or 2) Random assignment to 1 individual standard assessment/evaluation session.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Individuals will be eligible for the protocol who:

  • Are seeking outpatient treatment for any substance use disorder
  • Are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped)
  • Are able to understand and provide written informed consent

Exclusion Criteria:

Individuals will be excluded who:

  • Are not sufficiently medically or psychiatrically stable to participate in outpatient treatment
  • Are seeking detoxification only, methadone maintenance treatment or residential inpatient treatment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00032981

Locations
United States, California
Haight Ashbury Free Clinics
San Francisco, California, United States, 94117
Tarzana Treatment Center
Tarzana, California, United States, 91356
United States, Connecticut
LMG Programs, Inc.
Stamford, Connecticut, United States, 06901
CT Renaissance, Inc.
Norwalk, Connecticut, United States, 06852
United States, Pennsylvania
Rehab After Work
Philadelphia, Pennsylvania, United States, 19103
Northeast Treatment Center
Philadelphia, Pennsylvania, United States, 19123
Sponsors and Collaborators
Investigators
Principal Investigator: Kathleen Carroll, Ph.D. VA Connecticut Healthcare System
  More Information

Data Elements  This link exits the ClinicalTrials.gov site

Study ID Numbers: NIDA-CTN-0004-1
Study First Received: April 5, 2002
Last Updated: July 28, 2008
ClinicalTrials.gov Identifier: NCT00032981  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin

ClinicalTrials.gov processed this record on January 16, 2009